Differential absolute plasma IL-6 concentrations between two immunoassay platforms in intensive care unit patients with COVID-19

Objectives: Explore whether plasma IL-6 levels are similar across biomarker platforms and association with COVID-19 clinical outcomes. Methods: Plasma IL-6 concentrations were measured on 191 COVID-19 patients using the Roche Elecsys IL-6 assay and the Meso Scale Discovery assay. Results: Correlation of IL-6 levels between platforms was high (r = 0.87; 95% CI: 0.82–0.89); however, agreement was low (bias: 147.2 pg/ml; 95% limits of agreement: -489.5–783.9 pg/ml). The optimal IL-6 threshold to predict invasive mechanical ventilation and in-hospital mortality were 3- and 3.4-fold higher in Roche compared with Meso Scale Discovery, respectively. Conclusion: The absolute IL-6 threshold to predict outcomes was consistently higher using the Roche platform, and IL-6 thresholds to inform prognosis vary based on the biomarker platform.

[1]  M. Singer,et al.  Influence of IL-6 levels on patient survival in COVID-19 , 2021, Journal of Critical Care.

[2]  A. Iwasaki,et al.  Challenges in interpreting cytokine data in COVID-19 affect patient care and management , 2021, PLoS biology.

[3]  Peter J. Godolphin,et al.  Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis. , 2021, JAMA.

[4]  T. Aw,et al.  Performance of the Roche IL-6 chemiluminescent immunoassay in patients with COVID-like respiratory symptoms , 2021, Journal of Virological Methods.

[5]  B. Kestenbaum,et al.  Comparison of host endothelial, epithelial and inflammatory response in ICU patients with and without COVID-19: a prospective observational cohort study , 2021, Critical Care.

[6]  I. Douglas,et al.  Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia , 2021, The New England journal of medicine.

[7]  T. Cavero,et al.  IL-6 serum levels predict severity and response to tocilizumab in COVID-19: An observational study , 2020, Journal of Allergy and Clinical Immunology.

[8]  A. Barton,et al.  Predicting treatment response to IL6R blockers in rheumatoid arthritis , 2020, Rheumatology.

[9]  Keith Sigel,et al.  An inflammatory cytokine signature predicts COVID-19 severity and survival , 2020, Nature Medicine.

[10]  S. Jagannath,et al.  An inflammatory cytokine signature predicts COVID-19 severity and survival , 2020, Nature Medicine.

[11]  W. Kraus,et al.  Critical Appraisal of Four IL-6 Immunoassays , 2012, PloS one.